Last updated on December 2016

Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema


Brief description of study

This 2-part study will evaluate the safety and efficacy of an oral treatment, BCX7353, in preventing angioedema attacks in subjects with hereditary angioedema (HAE). In Part 1 of the study, eligible subjects will be randomized to receive oral BCX7353 or placebo for 4 weeks. Assuming successful completion of Part 1, additional subjects will be randomized in Part 2 to one of 2 lower doses of BCX7353 or placebo. The study will compare the number of acute attacks in each treatment group, as well as a number of other clinical and pharmacologic outcomes, and the safety and tolerability of each dose of BCX7353 compared to placebo.

Clinical Study Identifier: NCT02870972

Contact Investigators or Research Sites near you

Start Over

Clinical Trials

Adelaide, Australia
  Connect »

Clinical Trials

Campbelltown, Australia
  Connect »

Clinical Trials

Quebec City, Canada
  Connect »

Clinical Trials

Frankfurt, Germany
  Connect »

Clinical Trials

Budapest, Hungary
  Connect »

Clinical Trials

Skopje, Macedonia, The Former Yugoslav Republic of
  Connect »

Clinical Trials

Zürich, Switzerland
  Connect »

Clinical Trials

Brimingham, United Kingdom
  Connect »

Clinical Trials

Bristol, United Kingdom
  Connect »

Clinical Trials

London, United Kingdom
  Connect »

Clinical Trials

Oxford, United Kingdom
  Connect »

Clinical Trials

Southampton, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.